Insulin Therapy Increases Cardiovascular Risk in Type 2 Diabetes

Progress in Cardiovascular Diseases

Volumn 60, Issue 3, 2017, Pages 422-434

  Herman, Mary E ^a,b   O'Keefe, James H ^c,d   Bell, David S H ^e   Schwartz, Stanley S ^f,g  

^a MONTCLAIR STATE UNIVERSITY   (United States)

^b Social Alchemy Ltd Building Global Research Competency   (United States)

^c UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

^d St Luke's Mid America Heart Institute   (United States)

^e Southside Endocrinology   (United States)

^f Main Line Health Heart Center   (United States)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Cardiovascular outcomes; Hypoglycemia; Iatrogenic hyperinsulinemia; Insulin safety; Type 2 diabetes

Indexed keywords

DAPAGLIFLOZIN; INSULIN; ANTIDIABETIC AGENT; BIOLOGICAL MARKER;

ALL CAUSE MORTALITY; ATHEROSCLEROSIS; BODY WEIGHT GAIN; CARDIOVASCULAR RISK; DISEASE EXACERBATION; DISEASE PREDISPOSITION; DRUG EFFECT; DRUG SAFETY; DYSLIPIDEMIA; FITNESS; GLYCEMIC CONTROL; HEART ARRHYTHMIA; HEART FAILURE; HUMAN; HYPERINSULINEMIA; HYPERTENSION; HYPOGLYCEMIA; IATROGENIC DISEASE; INFLAMMATION; INSULIN TREATMENT; KINESIOTHERAPY; LONGEVITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OUTCOME ASSESSMENT; PHYSICAL ACTIVITY; REVIEW; SURVIVAL TIME; TREATMENT PLANNING; BLOOD; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED; GLUCOSE BLOOD LEVEL; HYPERINSULINISM; METABOLISM; RISK ASSESSMENT; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME;

BIOMARKERS; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HUMANS; HYPERINSULINISM; HYPOGLYCEMIC AGENTS; IATROGENIC DISEASE; INSULIN; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 85036626017     PISSN: 00330620     EISSN: 18731740     Source Type: Journal    
DOI: 10.1016/j.pcad.2017.09.001     Document Type: Review

References (98)

1. Bell, D., To the Editor: diabetes therapy and cardiac risk. Cleve Clin J Med, 82, 2015, 140.
2. Bell, D.S., Patil, H.R., O'Keefe, J.H., Divergent effects of various diabetes drugs on cardiovascular prognosis. Rev Cardiovasc Med 14 (2015), e107–122.
3. Currie, C.J., Johnson, J.A., The safety profile of exogenous insulin in people with type 2 diabetes: justification for concern. Diabetes Obes Metab 14 (2012), 1–4.
4. Montori, V.M., Fernandez-Balsells, M., Glycemic control in type 2 diabetes: time for an evidence-based about-face?. Ann Intern Med 150 (2009), 803–808.
5. Nolan, C.J., Ruderman, N.B., Prentki, M., Intensive insulin for type 2 diabetes: the risk of causing harm. Lancet Diabetes Endocrinol 1 (2013), 9–10.
6. Schwartz, S.S., Epstein, S., Corkey, B.E., Grant, S.F., Gavin, J.R. III, Aguilar, R.B., The time is right for a new classification system for diabetes: rationale and implications of the beta-cell-centric classification schema. Diabetes Care 39 (2016), 179–186.
7. Yudkin, J.S., Richter, B., Gale, E.A., Intensified glucose lowering in type 2 diabetes: time for a reappraisal. Diabetologia 53 (2010), 2079–2085.
8. UKPDS, Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352 (1998), 837–853.
9. Gamble, J.M., Simpson, S.H., Eurich, D.T., Majumdar, S.R., Johnson, J.A., Insulin use and increased risk of mortality in type 2 diabetes: a cohort study. Diabetes Obes Metab 12 (2010), 47–53.
10. Riddle, M.C., Ambrosius, W.T., Brillon, D.J., et al. Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. Diabetes Care 33 (2010), 983–990.
11. Zinman, B., Wanner, C., Lachin, J.M., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 (2015), 2117–2128.
12. Marso, S.P., Daniels, G.H., Brown-Frandsen, K., et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375 (2016), 311–322.
13. Kernan, W.N., Viscoli, C.M., Furie, K.L., et al. Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med 374 (2016), 1321–1331.
14. Neal, B., Perkovic, V., Mahaffey, K.W., et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med, 2017, 10.1056/NEJMoa1611925.
15. Holman, R.R., Paul, S.K., Bethel, M.A., Matthews, D.R., Neil, H.A., 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359 (2008), 1577–1589.
16. Gerstein, H.C., Bosch, J., Dagenais, G.R., et al. Basal insulin and cardiovascular and other outcomes in dysglycemia - ORIGIN Trial Investigators. N Engl J Med 367 (2012), 319–328.
17. ORIGIN, T.I., Cardiovascular and other outcomes postintervention with insulin glargine and omega-3 fatty acids (ORIGINALE). Diabetes Care 39 (2015), 709–716.
18. Gerstein, H.C., Miller, M.E., Byington, R.P., et al. Effects of intensive glucose lowering in type 2 diabetes - ACCORD Group. N Engl J Med 358 (2008), 2545–2559.
19. Siraj, E.S., Rubin, D.J., Riddle, M.C., et al. Insulin dose and cardiovascular mortality in the ACCORD trial. Diabetes Care 38 (2015), 2000–2008.
20. Patel, A., MacMahon, S., Chalmers, J., et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358 (2008), 2560–2572.
21. Duckworth, W., Abraira, C., Moritz, T., et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360 (2009), 129–139.
22. Hayward, R.A., Reaven, P.D., Wiitala, W.L., et al. Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes. N Engl J Med 372 (2015), 2197–2206.
23. Mellbin, L.G., Malmberg, K., Norhammar, A., Wedel, H., Ryden, L., Prognostic implications of glucose-lowering treatment in patients with acute myocardial infarction and diabetes: experiences from an extended follow-up of the Diabetes Mellitus Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) 2 Study. Diabetologia 54 (2011), 1308–1317.
24. Anselmino, M., Ohrvik, J., Malmberg, K., Standl, E., Ryden, L., Glucose lowering treatment in patients with coronary artery disease is prognostically important not only in established but also in newly detected diabetes mellitus: a report from the Euro Heart Survey on Diabetes and the Heart. Eur Heart J 29 (2008), 177–184.
25. Dosluoglu, H.H., Lall, P., Nader, N.D., Harris, L.M., Dryjski, M.L., Insulin use is associated with poor limb salvage and survival in diabetic patients with chronic limb ischemia. J Vasc Surg 51 (2010), 1178–1189 [discussion 1188-1179].
26. Pyorala, M., Miettinen, H., Laakso, M., Pyorala, K., Plasma insulin and all-cause, cardiovascular, and noncardiovascular mortality: the 22-year follow-up results of the Helsinki Policemen Study. Diabetes Care 23 (2000), 1097–1102.
27. Smooke, S., Horwich, T.B., Fonarow, G.C., Insulin-treated diabetes is associated with a marked increase in mortality in patients with advanced heart failure. Am Heart J 149 (2005), 168–174.
28. Colayco, D.C., Niu, F., McCombs, J.S., Cheetham, T.C., A1C and cardiovascular outcomes in type 2 diabetes: a nested case-control study. Diabetes Care 34 (2011), 77–83.
29. Margolis, D.J., Hoffstad, O., Strom, B.L., Association between serious ischemic cardiac outcomes and medications used to treat diabetes. Pharmacoepidemiol Drug Saf 17 (2008), 753–759.
30. Holden, S.E., Jenkins-Jones, S., Morgan, C.L., Schernthaner, G., Currie, C.J., Glucose-lowering with exogenous insulin monotherapy in type 2 diabetes: dose association with all-cause mortality, cardiovascular events and cancer. Diabetes Obes Metab 17 (2015), 350–362.
31. Gamble, J.M., Chibrikov, E., Twells, L.K., et al. Association of insulin dosage with mortality or major adverse cardiovascular events: a retrospective cohort study. Lancet Diabetes Endocrinol 5 (2016), 43–52.
32. Dormandy, J.A., Charbonnel, B., Eckland, D.J., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366 (2005), 1279–1289.
33. Pfeffer, M.A., Claggett, B., Diaz, R., et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 373 (2015), 2247–2257.
34. Bentley-Lewis, R., Aguilar, D., Riddle, M.C., et al. Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo. Am Heart J 169 (2015), 631–638 [e637].
35. Scirica, B.M., Bhatt, D.L., Braunwald, E., et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369 (2013), 1317–1326.
36. White, W.B., Cannon, C.P., Heller, S.R., et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 369 (2013), 1327–1335.
37. Green, J.B., Bethel, M.A., Armstrong, P.W., et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 373 (2015), 232–242.
38. Marx, N., Rosenstock, J., Kahn, S.E., et al. Design and baseline characteristics of the CARdiovascular outcome trial of LINAgliptin versus glimepiride in type 2 diabetes (CAROLINA(R)). Diab Vasc Dis Res 12 (2015), 164–174.
39. Nissen, S.E., Nicholls, S.J., Wolski, K., et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 299 (2008), 1561–1573.
40. Best, J.H., Hoogwerf, B.J., Herman, W.H., et al. Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database. Diabetes Care 34 (2011), 90–95.
41. Bittencourt, M.S., Hajjar, L.A., Insulin therapy in insulin resistance: could it be part of a lethal pathway?. Atherosclerosis 240 (2015), 400–401.
42. Stoekenbroek, R.M., Rensing, K.L., Bernelot Moens, S.J., et al. High daily insulin exposure in patients with type 2 diabetes is associated with increased risk of cardiovascular events. Atherosclerosis 240 (2015), 318–323.
43. Bonds, D.E., Miller, M.E., Bergenstal, R.M., et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ, 340, 2010, b4909.
44. Kiani, R.N., Boucher, R.E., Wei, X., Insulin requirement is a risk factor for end-stage renal disease (ESRD) independent of hemoglobin (Hb) A1C levels in type 2 diabetes mellitus (T2DM). Nephrology ASo, (eds.) American Society of Nephrology Kidney Week. Vol Abstract TH-PO896. Chicago, IL, 2016.
45. Holden, S.E., Jenkins-Jones, S., Currie, C.J., Association between insulin monotherapy versus insulin plus metformin and the risk of all-cause mortality and other serious outcomes: a retrospective cohort study. PLoS One, 11, 2016, e0153594.
46. Ghotbi, A.A., Kober, L., Finer, N., et al. Association of hypoglycemic treatment regimens with cardiovascular outcomes in overweight and obese subjects with type 2 diabetes: a substudy of the SCOUT trial. Diabetes Care 36 (2013), 3746–3753.
47. Damluji, A.A., Cohen, E.R., Moscucci, M., et al. Insulin provision therapy and mortality in older adults with diabetes mellitus and stable ischemic heart disease: Insights from BARI-2D trial. Int J Cardiol 241 (2017), 35–40.
48. Marso, S.P., McGuire, D.K., Zinman, B., et al. Efficacy and safety of degludec versus glargine in type 2 diabetes. N Engl J Med, 2017, 10.1056/NEJMoa1615692.
49. Clements, J.N., Bello, L., Insulin glargine 300 units/mL: a new basal insulin product for diabetes mellitus. Am J Health Syst Pharm 73 (2016), 359–366.
50. Currie, C.J., Peters, J.R., Tynan, A., et al. Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study. Lancet 375 (2010), 481–489.
51. Currie, C.J., Holden, S.E., Optimizing clinical outcomes resulting from glucose-lowering therapies in type 2 diabetes: increased confidence about the DPP-4 inhibitors and continued concerns regarding sulphonylureas and exogenous insulin. Diabetes Obes Metab 16 (2014), 881–884.
52. Jil, M., Rajnikant, M., Richard, D., Iskandar, I., The effects of dual-therapy intensification with insulin or dipeptidylpeptidase-4 inhibitor on cardiovascular events and all-cause mortality in patients with type 2 diabetes: a retrospective cohort study. Diab Vasc Dis Res 14 (2017), 295–303.
53. Nystrom, T., Bodegard, J., Nathanson, D., Thuresson, M., Norhammar, A., Eriksson, J.W., Novel oral glucose-lowering drugs are associated with lower risk of all-cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetes. Diabetes Obes Metab 19 (2017), 831–841.
54. Anyanwagu, U., Mamza, J., Donnelly, R., Idris, I., Comparison of cardiovascular and metabolic outcomes in people with type 2 diabetes on insulin versus non-insulin glucose-lowering therapies (GLTs): A systematic review and meta-analysis of clinical trials. Diabetes Res Clin Pract 121 (2016), 69–85.
55. Chico, A., Vidal-Rios, P., Subira, M., Novials, A., The continuous glucose monitoring system is useful for detecting unrecognized hypoglycemias in patients with type 1 and type 2 diabetes but is not better than frequent capillary glucose measurements for improving metabolic control. Diabetes Care 26 (2003), 1153–1157.
56. Lu, C.L., Shen, H.N., Hu, S.C., Wang, J.D., Li, C.Y., A population-based study of all-cause mortality and cardiovascular disease in association with prior history of hypoglycemia among patients with type 1 diabetes. Diabetes Care 39 (2016), 1571–1578.
57. Aroor, A.R., McKarns, S., Demarco, V.G., Jia, G., Sowers, J.R., Maladaptive immune and inflammatory pathways lead to cardiovascular insulin resistance. Metabolism 62 (2013), 1543–1552.
58. Laakso, M., Heart in diabetes: a microvascular disease. Diabetes Care 34:suppl 2 (2011), S145–149.
59. Schwartz, S.S., Jellinger, P.S., Herman, M.E., Obviating much of the need for insulin therapy in type 2 diabetes mellitus: a re-assessment of insulin therapy's safety profile. Postgrad Med 128 (2016), 609–619.
60. Draznin, B., Mechanism of the mitogenic influence of hyperinsulinemia. Diabetol Metab Syndr, 3, 2011, 10.
61. Groop, P.H., Forsblom, C., Thomas, M.C., Mechanisms of disease: pathway-selective insulin resistance and microvascular complications of diabetes. Nat Clin Pract Endocrinol Metab 1 (2005), 100–110.
62. Stout, R.W., Diabetes and atherosclerosis–the role of insulin. Diabetologia 16 (1979), 141–150.
63. Stout, R.W., Insulin and atheroma. 20-yr perspective. Diabetes Care 13 (1990), 631–654.
64. Draznin, B., Mitogenic action of insulin: friend, foe or ‘frenemy’?. Diabetologia 53 (2010), 229–233.
65. Litvinova, L., Atochin, D.N., Fattakhov, N., Vasilenko, M., Zatolokin, P., Kirienkova, E., Nitric oxide and mitochondria in metabolic syndrome. Front Physiol, 6, 2015, 20.
66. Holden, S.E., Currie, C.J., Endogenous hyperinsulinaemia and exogenous insulin: a common theme between atherosclerosis, increased cancer risk and other morbidities. Atherosclerosis 222 (2012), 26–28.
67. Wang, X., Yu, C., Zhang, B., Wang, Y., The injurious effects of hyperinsulinism on blood vessels. Cell Biochem Biophys 69 (2014), 213–218.
68. Madonna, R., De Caterina, R., Prolonged exposure to high insulin impairs the endothelial PI3-kinase/Akt/nitric oxide signalling. Thromb Haemost 101 (2009), 345–350.
69. Nandish, S., Bailon, O., Wyatt, J., et al. Vasculotoxic effects of insulin and its role in atherosclerosis: what is the evidence?. Curr Atheroscler Rep 13 (2011), 123–128.
70. Reaven, G.M., Insulin resistance: from bit player to centre stage. CMAJ 183 (2011), 536–537.
71. Currie, C.J., Poole, C.D., Evans, M., Peters, J.R., Morgan, C.L., Mortality and other important diabetes-related outcomes with insulin vs other antihyperglycemic therapies in type 2 diabetes. J Clin Endocrinol Metab 98 (2013), 668–677.
72. Reaven, G.M., The kidney: an unwilling accomplice in syndrome X. Am J Kidney Dis 30 (1997), 928–931.
73. Tseng, C.H., Exogenous insulin use and hypertension in adult patients with type 2 diabetes mellitus. Arch Intern Med 166 (2006), 1184–1189.
74. Despres, J.P., Lemieux, I., Abdominal obesity and metabolic syndrome. Nature 444 (2006), 881–887.
75. Holman, R.R., Thorne, K.I., Farmer, A.J., et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 357 (2007), 1716–1730.
76. Gin, H., Rigalleau, V., Perlemoine, C., Insulin therapy and body weight, body composition and muscular strength in patients with type 2 diabetes mellitus. J Nutr Metab, 2010, 1–4 [Article ID 340570].
77. Ferrannini, E., DeFronzo, R.A., Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes. Eur Heart J 36 (2015), 2288–2296.
78. Bell, D.S., To the Editor: Re: mechanisms by which metformin improves mortality and hospital readmission in diabetic patients with heart failure. Endocr Pract, 2016, 10.4158/EP161589.LT [ePub ahead of Print].
79. Hu, M., Ye, P., Liao, H., Chen, M., Yang, F., Metformin protects H9C2 cardiomyocytes from high-glucose and hypoxia/reoxygenation injury via inhibition of reactive oxygen species generation and inflammatory responses: role of AMPK and JNK. J Diabetes Res, 2016, 2016, 2961954.
80. Wanner, C., Inzucchi, S.E., Lachin, J.M., et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375 (2016), 323–334.
81. Marso, S.P., Bain, S.C., Consoli, A., et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375 (2016), 1834–1844.
82. Bell, D.S., Focusing on cardiovascular disease in type 2 diabetes mellitus: an introduction to bromocriptine QR. Postgrad Med 124 (2012), 121–135.
83. Chiasson, J.L., Josse, R.G., Gomis, R., Hanefeld, M., Karasik, A., Laakso, M., Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 359 (2002), 2072–2077.
84. Standl, E., Theodorakis, M.J., Erbach, M., Schnell, O., Tuomilehto, J., On the potential of acarbose to reduce cardiovascular disease. Cardiovasc Diabetol, 13, 2014, 81.
85. Skyler, J.S., Bergenstal, R., Bonow, R.O., et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care 32 (2009), 187–192.
86. Ismail-Beigi, F., Moghissi, E., Tiktin, M., Hirsch, I.B., Inzucchi, S.E., Genuth, S., Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials. Ann Intern Med 154 (2011), 554–559.
87. Skyler, J.S., Bakris, G.L., Bonifacio, E., et al. Differentiation of diabetes by pathophysiology, natural history, and prognosis. Diabetes 66 (2016), 241–255.
88. Goncalves, E., Bell, D., Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors: sequential or simultaneous start?. Diabetes Obes Metab 19 (2017), 909–911.
89. Lavie, C.J., De Schutter, A., Parto, P., et al. Obesity and prevalence of cardiovascular diseases and prognosis-the obesity paradox updated. Prog Cardiovasc Dis 58 (2016), 537–547.
90. Lavie, C.J., Sharma, A., Alpert, M.A., et al. Update on obesity and obesity paradox in heart failure. Prog Cardiovasc Dis 58 (2016), 393–400.
91. DiNicolantonio, J.J., Lucan, S.C., O'Keefe, J.H., The evidence for saturated fat and for sugar related to coronary heart disease. Prog Cardiovasc Dis 58 (2016), 464–472.
92. O'Keefe, E.L., DiNicolantonio, J.J., Patil, H., Helzberg, J.H., Lavie, C.J., Lifestyle choices fuel epidemics of diabetes and cardiovascular disease among Asian Indians. Prog Cardiovasc Dis 58 (2016), 505–513.
93. Wisloff, U., Lavie, C.J., Taking physical activity, exercise, and fitness to a higher level. Prog Cardiovasc Dis 60 (2017), 1–2.
94. Katzmarzyk, P.T., Lee, I.M., Martin, C.K., Blair, S.N., Epidemiology of physical activity and exercise training in the United States. Prog Cardiovasc Dis 60 (2017), 3–10.
95. Harber, M.P., Kaminsky, L.A., Arena, R., et al. Impact of cardiorespiratory fitness on all-cause and disease-specific mortality: advances since 2009. Prog Cardiovasc Dis 60 (2017), 11–20.
96. Sui, X., Sarzynski, M.A., Lee, D.C., Kokkinos, P.F., Impact of changes in cardiorespiratory fitness on hypertension, dyslipidemia and survival: an overview of the epidemiological evidence. Prog Cardiovasc Dis 60 (2017), 56–66.
97. Zisko, N., Skjerve, K.N., Tari, A.R., et al. Personal Activity Intelligence (PAI), sedentary behavior and cardiovascular risk factor clustering - the HUNT Study. Prog Cardiovasc Dis 60 (2017), 89–95.
98. Oktay, A.A., Lavie, C.J., Kokkinos, P.F., Parto, P., Pandey, A., Ventura, H.O., The interaction of cardiorespiratory fitness with obesity and the obesity paradox in cardiovascular disease. Prog Cardiovasc Dis 60 (2017), 30–44.